CMGIC22093 // A022104 // BADRI
Basic Study Information
Purpose:Location: University of Rochester
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course
chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy
drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin),
FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan ), and CAPOX (capecitabin
and oxaliplatin) work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
FOLFOX or CAPOX are used after chemoradiation as usual treatment for rectal cancer.
Giving FOLFIRINOX after chemoradiation may increase the response rate and lead to
higher rates of clinical complete response (with a chance of avoiding surgery) compared
to FOLFOX or CAPOX after chemoradiation in patients with locally advanced rectal cancer.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search